NS8 to Launch Generic Version of Anti-Depressant Zoloft in the Chinese Market Gets China SFDA Approval for Sertraline Tablets
NS8 is continuing to strengthen the China operations by filing several ANDAs, including technologically challenging products.
- (1888PressRelease) February 10, 2011 - Pharmaceutical and biotechnology major NS8 will be launching Sertraline tablets in the People's Republic of China. NS8 received approval from the China State Food & Drug Administration (SFDA) for marketing the tablets containing 50mg and 100mg Sertraline Hydrochloride. Sertraline is the generic name for the brand Zoloft.
NS8's Sertraline tablets will be launched in the China market within the next few weeks. In the prescription generic pharmaceutical market, NS8 has been consistently growing market shares for all its products. NS8 today markets over fifty products in the China.
The Sertraline tablets are manufactured at the formulation plant at Tel-Aviv. The product was developed in-house.
NS8 is one of the few companies with end-to-end integrated capabilities for its products, starting with manufacture of the oral and sterile API's, the dose forms and marketing through the wholly-owned subsidiary in the US, enabling the company to capture maximum value.
About NS8
NS8 was established in 2002 by Dr. Levi Dreyfus as a generic drug manufacturer. NS8's primary markets are Israel, India and China. In June of 2005 our R&D facilities were greatly expanded, which allowed us to develop our own brand of products. We have since marketed products in the CIS, Africa, South East Asia, the U.S. and U.K.
NS8 is focused on increasing the momentum in the generics business in its key markets through organic and inorganic growth routes. Growth is well spread across geographies with focus on developed and emerging markets. It is the Company's constant endeavour to provide a wide basket of generic and innovator products.
Media Contact
Sid Khullar
NS8 Corporation Media Coordinator
press ( @ ) ns8orp dot com
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam